Treatment of Refractory Obsessive-Compulsive Disorder with Nutraceuticals (**TRON**): A 20-week, open label pilot study

Authors: Jerome Sarris^{1,2}, Gerard J. Byrne^{3,4}, Georgina Oliver², Lachlan Cribb², Scott Blair-West², David Castle^{5,6}, Olivia M Dean⁷, David A. Camfield⁷, Vlasios Brakoulis^{8, 9}, Chad Bousman¹⁰, Nathan Dowling², Carolyn Ee¹, Jenifer Murphy², Ranjit Menon², Michael Berk^{7,11,12}, Suneel Chamoli³, Mark Boschen¹³, and Chee H. Ng²

1. Western Sydney University, NICM Health Research Institute, Westmead, NSW, Australia
2. Professorial Unit, The Melbourne Clinic, Department of Psychiatry, The University of Melbourne, Melbourne, Victoria, Australia
3. University of Queensland Centre for Clinical Research, Royal Brisbane & Women's Hospital, Brisbane, Australia
4. Mental Health Service, Royal Brisbane & Women's Hospital, Brisbane, Australia
5. Department of Psychiatry, University of Melbourne, Melbourne, Australia
6. Department of Psychiatry, St Vincent's Hospital, Melbourne, Australia
7. Deakin University, IMPACT – the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia.
8. Western Sydney Local Health District Mental Health Service, Sydney, Australia
9. School of Medicine Blacktown Hospital, Translational Health Research Institute (THRI), and Clinical and Health Psychology Research Initiative (CaHPRI), Western Sydney University.
10. Departments of Medical Genetics, Psychiatry, and Physiology & Pharmacology, University of Calgary, Calgary, AB, Canada
11. Florey Institute for Neuroscience and Mental Health, Kenneth Myer Building, Royal Parade, Parkville, Melbourne, Victoria, Australia.
12. Orygen, The National Centre of Excellence in Youth Mental Health and the Centre for Youth Mental Health Parkville, Melbourne, Victoria, Australia.
13. School of Applied Psychology, Griffith University, Gold Coast, QLD, Australia

Submitted 16 December 2020

Accepted 09 June 2021

Word Count: 4200

Tables: 4

DOI: 10.1017/S1092852921000638

This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, and so may be subject to change during the production process. The article may be cited using its DOI.

Figures: 2

Supplementary figure: 1

Declaration of Interests:

The authors declare no significant direct conflicts of interest. For general disclosures see the COI section.

Contact Information:

Prof Jerome Sarris

NICM Health Research Institute, Western Sydney University

Locked Bag 1797, Penrith, NSW 2751, Australia

Email: j.sarris@westernsydney.edu.au

Running Head: Nutraceutical Combination for Treatment-Resistant OCD

ABSTRACT

Background: Obsessive-compulsive disorder (OCD) is often challenging to treat and resistant to psychological interventions and prescribed medications. The adjunctive use of nutraceuticals with potential neuromodulatory effects on underpinning pathways such as the glutamatergic and serotonergic systems is one novel approach.

Objective: To assess the effectiveness and safety of a purpose-formulated combination of nutraceuticals in treating OCD: N-acetyl cysteine, L-theanine, zinc, magnesium, pyridoxal-5' phosphate and selenium.

Methods: A 20-week open label proof-of-concept study was undertaken involving 28 participants with treatment-resistant DSM-5-diagnosed OCD, during 2017-2020. The primary outcome measure was the Yale-Brown Obsessive-Compulsive Scale (YBOCS), administered every four weeks.

Results: A intention-to-treat analysis revealed an estimated mean reduction across time (baseline to week-20) on the YBOCS total score of -7.13 (95% confidence interval = -9.24, -5.01), with a mean reduction of -1.21 points per post-baseline visit ($p \leq 0.001$). At 20-weeks, 23% of the participants were considered 'responders' (YBOCS $\geq 35\%$ reduction and 'very much' or 'much improved' on the Clinical

Accepted Manuscript: Authors' Copy

72 Global Impression – Improvement scale). Statistically significant improvements were also revealed on
73 all secondary outcomes (e.g. mood, anxiety, quality of life). Notably, treatment response on OCD
74 outcome scales (e.g. YBOCS) was greatest in those with lower baseline symptom levels, while response
75 was limited in those with relatively more severe OCD.

76 **Conclusion:** While this pilot study lacks placebo-control, the significant time effect in this treatment-
77 resistant OCD population is encouraging and suggests potential utility especially for those with lower
78 symptom levels. Our findings need to be confirmed or refuted via a follow-up placebo-controlled study.

79

80

81 **Trial Registry:** ACTRN 12613000310763

82

83 **Key words:** Nutrients, OCD, Zinc, Vitamins, Treatment-Resistant, Anxiety

84 **Running Head:** Nutraceutical Combination for Treatment-Resistant OCD

85

1. Introduction

Although first line therapies for OCD, including serotonin re-uptake inhibitors (SRIs) (selective serotonin re-uptake inhibitors (SSRIs) and clomipramine), and/or psychological interventions (specifically exposure-response prevention; ERP) can elicit clinically meaningful improvements in many patients,^{1,2} a proportion remain 'treatment-resistant'.^{3,4} The terms 'treatment-resistant' and 'treatment refractory' are often used interchangeably in research and clinical practice, but the latter has been described as a greater degree of treatment resistance in which patients have failed to attain adequate improvements with three SRI trials (one of which includes clomipramine), two antipsychotic augmentation strategies as well as CBT therapy concurrent to pharmacotherapy.⁵

Although there is a paucity of research into the aetiopathogenesis of treatment-resistant or refractory OCD, positive treatment responses have been demonstrated for glutamatergic modulating pharmacotherapies.⁶ Abnormalities of glutamatergic activity may exist in some treatment refractory individuals. In addition, the presence of oxidative stress, which may be greater in magnitude in more chronic and severe cases of OCD warrants further investigation as a treatment target.⁷ Thus, strategies which modulate glutamate activity and provide antioxidant and neuroprotective effects may be of benefit in patients with treatment-resistant and refractory OCD. One approach is the use of nutraceutical agents, which have been shown to be potentially effective adjuncts in a range of psychiatric disorders, including depression.⁸ Further the use of 'combination' nutraceuticals may potentially exert a greater effect than isolated nutrients via targeting an array of neurobiological pathways underlying the disorder, and

Accepted Manuscript: Authors' Copy

potentially via synergism (as nutrients are often more effective in combination and may require certain nutrient co-factors for optimal metabolism).⁹

Key nutraceuticals with the potential to modulate implicated pathways involved in OCD include: N-acetyl cysteine (NAC), zinc, L-theanine, selenium, magnesium, and pyridoxal-5' phosphate (P5P). In brief, NAC has been found to attenuate the synaptic release of glutamate in subcortical brain regions (via glutamate metabotropic autoreceptor 2/3 activation and the involvement of cysteine transporters) and restore extracellular concentrations of glutamate in the nucleus accumbens.¹⁰⁻¹² The latter mechanism is postulated to be particularly beneficial for attenuation of compulsive behaviours.¹² Neuroimaging studies highlight NAC's ability to exert activity in the brain when taken orally. For example, oral administration of NAC in adults can lower elevated levels of glutamate in the dorsal anterior cingulate cortex (dACC), as well as glutamate plus glutamine levels in the anterior cingulate cortex (ACC).^{13,14} L-theanine is a nonproteinogenic amino acid derived almost exclusively from tea leaves (*Camellia sinensis*) and possesses various neuromodulatory and neuroprotective effects, particularly enhancing inhibitory and attenuating excitatory neurotransmission.¹⁵ Specifically, L-theanine is a glutamate analogue which exerts weak antagonistic effects at ionotropic glutamate receptor subtypes, and has a stronger affinity for inhibiting glutamine transporter activity, which subsequently suppresses exocytotic release of glutamate.^{16,17}

Zinc is an essential trace mineral involved in a diverse range of biochemical processes.¹⁸ It is a modulator of inhibitory and excitatory neurotransmission with effects on glutamate and GABA, which may in part explain its role in the attenuation of excitotoxicity.^{19,20} A deficiency of dietary

Accepted Manuscript: Authors' Copy

zinc has also been implicated in the excitability of glutamatergic neurons.²¹ Further, zinc is involved in antioxidant and anti-inflammatory processes, including as a structural component of superoxide dismutase, maintaining metallothionein concentrations in tissues, sequestering the production of reactive oxygen species, inhibiting glutathione depletion and protecting against lipid peroxidation in the brain.^{22,23} One small RCT in OCD revealed that zinc supplementation potentiated the effects of fluoxetine in individuals with moderately severe OCD (minimum score of 21 on the YBOCS at time of entry), which was significant within 2-weeks of administration.²⁴ In addition, serum zinc levels were significantly lower in individuals with OCD compared to healthy controls matched for sex, age and socioeconomic status.²⁵

Selenium is an essential trace mineral which interacts primarily with a class of enzymes and transporters called 'selenoproteins', many of which are essential antioxidant enzymes. It is an integral part of the key redox enzymes thioredoxin reductase and GSH peroxidases, and also possesses anti-inflammatory activity through suppression of COX-2 enzymes.²⁶ Low serum levels of selenium have been detected in some individuals with OCD, and a deficient state of this mineral have been associated with the development of oxidative stress.²⁷ Further, in selenium deficient states, the pro-inflammatory COX-2 enzyme becomes upregulated and susceptibility to glutamate induced neurotoxicity increases, which may result in loss of hippocampal neurons and damage to glial cells.²⁸

Magnesium is an essential dietary mineral and serves as an enzymatic co-factor in over 300 biochemical reactions, most notably in adenosine triphosphate and adenylyl cyclase dependent enzymes.²³ Its neurobiological activity includes inhibitory effects at NMDA receptors, and thus,

Accepted Manuscript: Authors' Copy

attenuation of extracellular glutamate release with subsequent neuroprotective effects, particularly in the hippocampus.^{29,30} Magnesium supplementation in mice attenuates anxiety-related behaviours and modulates glutamatergic and GABAergic transmission, as well as the activity of the hypothalamic-pituitary axis.^{31,32} P5P, or 'activated vitamin B6', is the phosphorylated form of pyridoxal (the oxidised form of pyridoxine; vitamin B6) and serves as a cofactor in more than 150 enzymatic reactions.³³ P5P is a rate limiting cofactor in the synthesis of various neurotransmitters, including decarboxylation reactions required in the production of dopamine, serotonin and GABA as well as noradrenaline and melatonin.³⁴ Even a mild deficiency of this vitamin may result in down-regulation of GABA and serotonin synthesis and subsequent disturbances in sleep, behaviour, and cardiovascular function, with a loss of hypothalamus-pituitary control of hormone excretion.³⁴

This 20-week, multi-centre open-label clinical trial sought to elucidate the effects of a nutraceutical combination of the aforementioned nutrients, for individuals with treatment-refractory OCD (TR-OCD). This preliminary study was open label given the severe and chronic nature of TR-OCD and necessity for additional evidence-based treatment approaches for these individuals.^{35,36} Several other clinical trials involving TR-OCD participants have adopted this research design.³⁷⁻⁴⁰ Open label designs are arguably more ethical in OCD than in other psychiatric disorders because of very low placebo response rates in OCD.^{41,42} It was hypothesized that the nutraceutical combination would attenuate symptoms of OCD as measured by a reduction in YBOCS score from baseline to week-20 endpoint. Additional benefits were anticipated for alleviating anxiety as well as improving mood, general functioning, and overall quality of life.

2. Methods

2.1 Participants

Eligible participants were between the ages of 18 and 75 years with a primary diagnosis of OCD (confirmed with the Structured Clinical Interview for the DSM-5; SCID-5) of moderate or greater severity (YBOCS ≥ 16) who had the desire and capacity to consent to the study and follow its procedures. Participants had treatment refractory OCD, defined as inadequate responses to a minimum of three trials of SRIs, one augmentation strategy (e.g. an antipsychotic or mood stabilizer) as well as engagement in adequate CBT therapy specific for OCD (e.g. completion of an inpatient OCD program or minimum 15 sessions of outpatient ERP). Treatment refractory criteria for the trial were formulated from the current literature at the time of protocol development and group consensus from the study psychiatrists experienced in OCD treatment. Participants who were already receiving standard treatment for their OCD, for example, psychotropic medication or ERP, were required to be stable prior to entry into the trial (minimum 12 weeks at consistent doses and/or frequency of therapy). Participants were excluded if they had a diagnosis of bipolar disorder, a psychotic disorder, primary diagnosis of an obsessive-compulsive spectrum disorder/s (secondary diagnosis permitted); current alcohol/substance abuse (as per SCID-5); suicidal ideation SIGHD-17 score ≥ 3 ; were allergic to, or taking medications with known or suspected negative interactions with any of the investigated nutraceuticals (for example anticoagulants such as warfarin); had a serious or unstable medical condition/s; current gastrointestinal ulcers; pregnancy and lactation. Further, participants were withdrawn from the study if they experienced a severe deterioration in their OCD (medical monitors were notified if there was a $\geq 25\%$ increase in their YBOCS score from baseline); ceased taking the nutraceuticals

Accepted Manuscript: Authors' Copy

for 7+ days; underwent substantial treatment changes (for example, change in primary medication or entry into an inpatient OCD CBT program); emergence of serious side effects/SAEs as (determined by the medical monitors on a case by case basis); or if a participant elected to withdraw from the trial at their own volition.

2.2. Intervention

Treatment consisted of the nutraceutical combination taken each day for the 20-week study period in an open-label manner. The nutraceuticals were taken together in combination, and used adjunctively to existing psychotropic medication/s, psychological therapy, or as a monotherapy. Table 1 details the investigated nutraceuticals and dosages used.

The NAC and L-theanine capsules were supplied by BioCeuticals® in line with strict pharmaceutical Good Manufacturing Practices (GMP). The Zinc (Zinc Drops), Selenium (Selenium Drops) and Magnesium + P5P (Ultra Musceleze® P5P) tablets were also produced and supplied by BioCeuticals®, in line with strict pharmaceutical GMP.

2.3 Measures

2.3.1 Baseline measures. After providing written, informed consent, participants' demographic information was obtained including age, gender, education level, marital and employment status, country of birth and ancestry. A medical, mental health and treatment history was also obtained. Height and weight (to calculate body mass index [BMI]) and blood pressure were also recorded at baseline. The NetSCID-5,⁴³ a computerized version of the SCID-5, was used to confirm the diagnosis of OCD, screen for exclusionary disorders applicable the study (psychosis, bipolar disorder, substance abuse/dependence) and to determine the presence of comorbidities.

Accepted Manuscript: Authors' Copy

A condensed version of the SCID-5 was administered using the following DSM-5 diagnostic modules: mood disorders, psychotic disorders, substance use disorders, anxiety disorders, obsessive-compulsive and related disorders and gambling disorder.

2.3.2 Outcome measures. The Yale-Brown Obsessive-Compulsive Scale (YBOCS) – severity scale⁴⁴ was used as the primary outcome measure. The YBOCS severity scale is a 10-item, semi-structured, clinician administrated instrument that is regarded as the gold standard for measuring the severity of obsessive and compulsive symptoms.⁴⁵ The self-reported Dimensional Obsessive-Compulsive Scale (DOCS)⁴⁶ was used to capture dimensional or thematic aspects of OCD symptoms as well as their perceived severity. The DOCS assesses the following symptom dimensions: germs and contamination; responsibility for harm, injury, or bad luck; unacceptable obsessional thoughts; symmetry, completeness, and exactness. Depressive symptoms were assessed using the Structured Interview Guide for the Hamilton Depression Rating Scale (SIGHD-17). Physiological and psychological anxiety symptoms were assessed using the 21-item, self-reported Beck Anxiety Inventory (BAI).⁴⁷ The Sheehan Disability Scale (SDS)⁴⁸ was used to measure the extent of which three domains (work; social life or leisure activities; and home life or family responsibilities) were impaired by mental health symptoms as perceived by the participant. The clinician rated Clinical Global Impression scale (CGI) and patient rated Patient Global Impression scale (PGI) were used to rate OCD severity and change relative to baseline.^{49,50} Quality of life was assessed using the 25-item, self-reported World Health Organization Quality of Life – BREF (WHOQOL-BREF).⁵¹ Adverse events (AEs) were described qualitatively by the participant at the start of each post-baseline visit. AEs were further assessed using the self-reported Systematic Assessment for Treatment Emergent Events (SAFTEE),⁵² a 55-item symptom

Accepted Manuscript: Authors' Copy

checklist assessing the presence and severity of emerging side effects. Caffeine was measured in milligrams based on standard amounts found in beverages e.g., instant coffee = 60mg, black tea = 40mg.

2.4 Procedures

The study was a 20-week, open-label, multicentre, pilot study conducted at The Melbourne Clinic (TMC) Professorial Unit in Melbourne, VIC (University of Melbourne); The Royal Brisbane and Women's Hospital in Brisbane, QLD (University of Queensland) and NICM Heath Research Institute, Westmead, NSW (Western Sydney University). Recruitment occurred between August 2017 to May 2020. The study was registered on the ANZCTR (ACTRN12617001140347) and approved by TMC Research Ethics Committee (290), WSU Human Research Ethics Committee (H12331) and UQ Medical Research Ethics Committee (2018000339) prior to recruitment.

Participants were recruited via invitation letters to past attendees of an OCD inpatient program at TMC, clinician referrals at each recruitment site, as well as radio and Facebook advertising. Those who expressed interest in study participation completed a brief phone screening assessment with a research assistant to review their treatment and medical history to gauge study suitability. Baseline screening appointments were scheduled thereafter. After providing written informed consent, participants were assessed by a research assistant (trained via workshops led by clinicians experienced in OCD assessment) at baseline and every four weeks thereafter throughout the 20-week intervention using the measures outlined above. At each follow-up visit participants were asked about any significant life events, notable changes in OCD symptoms, the presence of side effects/new symptoms since last visit, healthcare visits,

Accepted Manuscript: Authors' Copy

treatment changes, and compliance (i.e. recalled missed doses of the nutraceuticals). Alcohol, drug use, and average daily caffeine intake were also estimated at each study visit, and blood pressure taken. At week-8, participants who had not experienced a $\geq 35\%$ reduction in their YBOCS score from baseline were titrated from 2 capsules twice per day to 3 capsules twice per day (where tolerable), of the NAC & L-theanine capsules (max dose equating to 3,000mg of NAC and 600mg of L-theanine per day).

Participants were asked to return remaining nutraceuticals at the end of the study to estimate adherence. Further, at the end of the 20-weeks, participants were entitled to an additional supply of the nutraceuticals (3 containers of NAC & L-theanine capsules, 1 bottle of Zinc liquid, 1 bottle of Selenium liquid, 1 bottle of Magnesium with P5P 'Ultramuscleze' [BioCeuticals®]) accompanied by a letter with recommended dosage instructions as specified by the Therapeutic Good Administration (Australia) and general safety information. The letter also advised the participant to discuss with their treating doctor prior to continuing the nutraceuticals post-study completion.

2.5 Data & statistical analysis

The analysis of primary and secondary outcomes was undertaken using linear mixed effects models (LMMs; R package *lme4*⁵³) and included all participants with outcome data available. Models included a random intercept term. Such models account for correlated measurements within individuals and allow for the use of all available data. For each model, the outcome of interest was the fixed effect of 'time' which represented the mean change in symptoms between study visits. LMMs included baseline score as a covariate and a baseline score-by-time

Accepted Manuscript: Authors' Copy

interaction (to allow treatment response to depend on baseline severity). For the primary outcome (total YBOCS), we also investigated an interaction between time and baseline caffeine intake, and time and number of prior failed medication therapies, to determine whether either variable modified treatment response. The likelihood ratio test was used to determine whether treatment response followed a linear trend. In the absence of clear evidence of non-linearity, time was modelled as linear. A sample size calculation was not performed as we sort to recruit as many eligible people as possible to this pilot study within our 3-year recruitment window.

Completed secondary outcome scales included occasional missed responses for some scale items. Across all visits and participants, a total of 9 items were missed on the DOCS, two on the SIGHD, four on the BAI and six on the SDS (< 1% missing for each outcome). These missed item responses were imputed using predictive mean matching (R package *mice*⁵⁴) prior to calculating total scores. Imputation was only used for completed outcome scales with no more than one-third missed items, and not for scales which were not completed (for instance, due to participant drop-out). For outcomes in which treatment response depended on baseline symptom severity, the estimated follow-up scores were calculated with the baseline score at its mean. Treatment response was defined as a $\geq 35\%$ reduction in Y-BOCS as well as a CGI-I rating of 1 ("very much improved") or 2 ("much improved") at study endpoint.⁵⁵ We additionally used the criteria of Jacobson and Truax⁵⁶ to evaluate the proportion of participants with 'reliable' and 'clinically significant' change at study endpoint. A change ≥ 10 points on the YBOCS constituted a reliable change and a final total YBOCS score ≤ 14 constituted a clinically significant change (as YBOCS scores below this threshold are closer to the normal mean than the clinical mean).⁵⁷ For the primary outcome we performed a sensitivity per-protocol analysis, including only participants

with high (>75%) treatment compliance. Additionally, because of the large proportion of study non-completers, we performed a sensitivity analysis to assess the impact of dropout. This sensitivity analysis was performed using a pattern-mixture model in which intercepts and slopes are estimated separately for study completers and non-completers and the results are combined in a weighted average.⁵⁸ A *p* value of <0.05 was considered statistically significant. All statistical analysis was performed using R version 4.0.2⁵⁹ and plots were produced using R packages *sjPlot*⁶⁰ and *ggplot2*.⁶¹

3. Results

3.1 Participant characteristics

A total of 975 people initially expressed interest in the trial, with only 30 participants being regarded as potentially meeting inclusion criteria (with many not meeting the criteria of TR-OCD). These 30 were assessed for study eligibility in a baseline screening appointment. Two participants were subsequently excluded during baseline assessment, one because of a SIGHD-17 suicide item score ≥ 3 , the other for deteriorating mental health symptoms. Both were referred to their treating psychiatrist for ongoing care. Thus, 28 participants met inclusion criteria and provided written informed consent to proceed with the trial. Baseline characteristics of the enrolled participants are shown in Tables 2 & 3.

Of the 28 participants, 13 (46%) completed the 20-week study intervention, and 15 (54%) were withdrawn at various stages for the following reasons (note, two participants had dual reasons for withdrawing): adverse events (*n* = 6), occurrence of an SAE warranting withdrawal as per study protocol/medical investigators (*n* = 2), participant decision due to lack of improvement in

OCD (n = 3), unable to attend follow-up visits (n = 3), lost to follow-up (n = 1), non-compliance with the IP (n = 1) and approaching expiry of the nutraceuticals (n = 1). Three of the 15 withdrawn participants did not attend a study visit after baseline. There were 13 (46.4%) participants whose treatment (NAC & L-theanine capsules) was titrated to a higher dose due to non-response at week 8.

3.2 Primary outcome

The primary LMM revealed that OCD symptom severity improved from baseline (mean = 25.9, SD = 5.05) to week-20 with a mean change in total YBOCS symptoms of -7.13 (95% CI = -9.24, -5.01, $p < 0.001$), for those with the mean severity at baseline. This was equivalent to a 28% drop in total YBOCS score for the overall group. The mean reduction in symptoms between post-baseline visits was -1.21 points (95% CI = -1.66, -0.764; $p < 0.001$). Estimated follow-up means are displayed in Table 4. Notably, there was a significant baseline YBOCS score by time interaction ($p = 0.005$), with the slope of treatment response greatest in those with lower symptom levels at baseline (see Figure 1). The estimated mean treatment response in those with mild baseline symptoms (baseline YBOCS = 20.6; 20th percentile) was -9.45 points (95% CI = -12.4, -6.48), while in those with more severe symptoms (baseline YBOCS = 28.6; 80th percentile) the mean change was -5.49 points (95% CI = -8.05, -2.94). After accounting for the interaction between baseline YBOCS score and time, treatment response was further modified by baseline caffeine intake. Higher baseline caffeine intake was associated with greater treatment response, with an increase of one interquartile range in daily caffeine intake (e.g., 50mg/day to 232mg/day; 25th to 75th percentile) associated with a 4.04-point greater reduction in YBOCS score over the trial ($p < 0.001$; see Figure S1 – supplementary material). There was no evidence

to suggest that treatment response was influenced by the number of prior unsuccessful medication trials (p interaction = 0.71), after accounting for the interaction between baseline YBOCS severity and time.

A total of three (23%) participants who completed the trial met criteria for response ($\geq 35\%$ reduction in total YBOCS scores and 'improved' or 'very much improved' on the CGI-I at the final visit) and an additional two (15%) met criteria for partial response ($> 25\%$ and $< 35\%$ reduction in total YBOCS scores). Finally, three (23%) were estimated to meet the Jacobson and Truax criteria for reliable and clinically significant change at endpoint.

In a per-protocol analysis, including only participants with good compliance ($>75\%$), the estimated mean change in total YBOCS was not substantively changed (mean change = -7.26, 95% CI = -9.53, -4.99, $p < 0.001$). Finally, in a pattern-mixture model assessing the influence of participant dropout, the mean change in total YBOCS score was reduced (mean change = -5.04, 95% CI = -8.45, -1.62, $p = 0.004$).

3.3 Secondary Outcomes

Estimated follow-up visit means and mean treatment response for all secondary outcomes are displayed in Table 4. Considering the YBOCS obsession and compulsion subscales, treatment response was greatest in those with lower symptom levels at baseline (p interaction = 0.085 and p interaction = 0.020, for obsession and compulsion subscales, respectively). Symptoms improved across the trial for both the obsession (mean change = -3.61; 95% CI = -4.83, -2.39; $p < 0.001$) and compulsion subscales (mean change = -3.50; 95% CI = -4.76, -2.24; $p < 0.001$), for those with mean baseline severity for each measure. For the DOCS, the slope of treatment response was similarly greatest in those with lower symptom levels at baseline (p interaction =

0.022; see Figure 2). The estimated mean change in symptoms for those with the mean baseline DOCS score was -9.23 (95% CI = -13.2, -5.25; $p < 0.001$). For the SIGHD and BAI, there was little evidence that treatment response depended on baseline severity (p interaction = 0.54 and p interaction = 0.18, respectively). For the SIGHD, depressive symptoms improved across the trial with a mean change across the trial of -5.38 (-7.16, -3.59, $p < 0.001$) points. For the BAI, the mean change across the trial was -9.80 (95% CI = -12.9, -6.73, $p < 0.001$) points. Finally, for the SDS, there was no clear evidence that treatment response depended on baseline severity (p interaction = 0.17). Self-reported disability improved over the trial with a mean change of -4.69 points (95% CI = -6.55, -2.83, $p < 0.001$).

On the clinician-rated CGI-I, three (25%) were rated as 'very much improved', with seven (58%) rated as 'minimally improved' and two (17%) rated as 'no change' at the final study visit (week-20). On the participant-rated PGI-I, one participant (8%) reported being 'very much better', five (42%) reported being 'much better', four (33%) reported being 'a little better' and the remaining two (17%) reported 'no change' at study completion. Finally, for item 1 of the WHOQOL-BREF ("How would you rate your quality of life?"), eight (67%) study completers reported a quality-of-life score higher than their initial baseline score, while quality of life for the remaining four (33%) of participants was unchanged.

3.4 Safety Data

Eight participants were withdrawn from the study due to adverse events. Three of these withdrawals were the participant's decision. One elected to withdraw due to feelings of

Accepted Manuscript: Authors' Copy

agitation, one due to sedation, nausea, and tachycardia, and one due to digestive complaints. Two participants were withdrawn by the study investigators, one for experiences of vivid dreams and fatigue, and a second for worsening physical and mental health and non-compliance with the nutraceuticals. A further participant withdrew based on advice from their general practitioner following an elevated C-reactive protein test. Finally, two participants experienced serious adverse events (SAEs) and were withdrawn from the study. The SAEs were both exacerbation in OCD symptoms requiring in-patient admission. Both events were deemed 'unlikely' to be related to the study treatment. Across the study, the most reported adverse events were nausea (n = 9), which was associated with vomiting in two participants, diarrhoea (n = 3), headache (n = 3), constipation (n = 3), reflux (n = 3) and gustatory disturbance (n = 3). Gastric adverse events were typically transient and resolved at subsequent visits (however two participants were withdrawn due to this reason). These adverse events often improved following advice to consume the nutrients with food.

4. Discussion

To our knowledge, this pilot study represents the first to explore the use of a nutraceutical combination for OCD, and particularly for a treatment-resistant population. Although our study was open-label, it is noteworthy that this sample had chronic treatment-resistant OCD symptoms, and thus any clinical improvement was clinically meaningful. Our results revealed that the combination of NAC, L-theanine, selenium, zinc, magnesium, and P5P had a modest clinical effect in respect to reducing OCD symptoms on both the YBOCS and the DOCS. It was also found to reduce depressed mood and anxiety and improve quality of life.

Accepted Manuscript: Authors' Copy

Of note is that treatment response appeared to depend on baseline severity with regard to OCD symptom outcomes (i.e. YBOCS, DOCS). However, there was no clear indication that baseline severity modified treatment response on other outcomes (SIGHD, BAI, SDS). Those with lower symptom levels may be more likely to benefit, and potentially could be deemed relatively less 'treatment-resistant'. This contrasts with the treatment of major depressive disorder, which tends to provide a greater relative symptom reduction with pharmacotherapies in cases of more severe symptomatology (whereas for milder symptom levels medication is equivalent to placebo).⁶² There was also evidence that those with higher baseline caffeine intake were substantially more responsive to the treatment than those with low baseline caffeine intake. Notably, two small double blind trials, one comparing caffeine to dextroamphetamine and one comparing caffeine with placebo, both found preliminary supportive evidence for the efficacy of caffeine in TR-OCD.^{63,64} This results suggests that it is plausible that there may have been a synergistic interaction between caffeine and the treatment formula in this study, particularly given that L-theanine is well known to interact synergistically with caffeine.⁶⁵ Exploring the nature of this potential synergism is a promising avenue for further research.

Our prior systematic review exploring the principal nutraceutical in this formulation (NAC) for OCD and related disorders (OCD⁶⁶) found that the balance of evidence supported the use of NAC in presentations of moderate-severity OCD and OCD⁶⁶, and a more recent meta-analysis supported a small but significant improvement in OCD symptoms from add-on NAC.⁶⁷ Doses of 2.4g-3g/day for a minimum of eight weeks were considered adequate for providing an initial therapeutic effect. However, even within these patient groups, response rates are variable, and some reports have not confirmed efficacy (particularly in treatment-resistant populations).

Accepted Manuscript: Authors' Copy

439 Additionally, our recent 16-week, double-blind RCT^{68,69} using 3 g/day of NAC (1.5 g twice daily) in
440 44 participants with DSM-5 diagnosed OCD, while revealing a nonsignificant time x treatment
441 interaction for the YBOCS scale total score, did show a significant time x treatment interaction
442 for the YBOCS 'Compulsions' subscale in favour of NAC at week-12 ($p = 0.013$). So, the question
443 remained in terms of whether additional nutraceuticals to NAC, with some potentially beneficial
444 mechanistic interaction would further enhance treatment efficacy beyond improvement of
445 compulsive symptoms. This study, while providing benefit in some individuals, needs to be
446 confirmed in a larger RCT in those with treatment-resistance. There is particular potential for its
447 application in those with lower OCD symptom levels.

448
449 Clinically, it is worth noting that several participants had gastrointestinal problems when
450 consuming the nutrient combination. While the 2g to 3g of NAC used in the study appeared to
451 be well-tolerated, it did potentially cause mild to moderate gastrointestinal effects. This was
452 noted to be the most common symptom in our previous NAC studies (potentially due to the
453 irritant effect of the sulphur-based compound). This was largely offset by the recommendation
454 of co-consumption with or after food (this irritation could also be due to the zinc). Further, some
455 symptoms, such as dizziness, agitation, and insomnia, were present in some participants, and
456 were likely unrelated to study medications as such symptoms are common in people with
457 anxiety or may be due to either a nocebo reaction or a psychosomatic experience in this
458 population. However, an interaction with medications such as SRIs (potentially increasing
459 serotonergic activation) are also possible. A future placebo-controlled study could elucidate this.

Accepted Manuscript: Authors' Copy

The current study has several limitations. Firstly, it was an open-label design (though as noted previously placebo response rates may be lower in OCD than comparable disorders, and such pilot studies are crucial to determine feasibility for future larger RCT designs).^{42,70} Another limitation was that while the study included people with OCD who were on “treatment as usual”, potential effect-modifying factors were present with participants taking different types of medications, or psychological interventions. The study was not adequately powered to assess differences in subgroups. Overall sample size was modest, and there was a high withdrawal rate, which is common in the more severe presentations of psychiatric disorders. This high withdrawal rate is a recognized limitation and may have led to estimated treatment effects being inflated, as participant withdrawal may have coincided with worsening mental health symptoms. Indeed, there was a 30% smaller estimated treatment effect in the pattern mixture model, which accounted for different treatment response between completers and non-completers. We also did not measure blood levels of relevant nutrients, as this would help to test the pharmacokinetics and serum levels in relation to efficacy, in addition to compliance. Regardless, our study had a 20-week interventional period, and thus should have duration long enough for any potential benefits to be apparent. Additionally, it is recognized that the pharmacokinetic and pharmacodynamic interaction between the nutrients (and potential synergy) is at present unknown and needs to be teased out in preclinical and clinical models. Other nutrients which have antioxidant effects potentially dampening glutaminergic neurotoxicity, such as vitamin C and B12, may also be of benefit. Finally, the treatment effects reported in this study are likely to be overstated as open-label trials are subject to bias by placebo effects and other non-specific effects (such as regression to the mean, Hawthorne effects, and disease natural course variation).⁷¹ OCD patients may have slow and steady improvements on SSRI treatments for

Accepted Manuscript: Authors' Copy

periods longer than 12 weeks, and so a longer waiting period for those who recently commenced new treatments may have been required.^{72,73} Strengths of the study include the use of a titration mechanism for those who were initially non-responsive, and that the use of a multi-nutrient combination provided the potential for synergistic neurobiological activity beyond the usual monotherapy approach. Further research to experiment with formulation adjustments and use in concert with ERP may also be beneficial.

In conclusion, this pilot study tentatively supports the benefits of nutraceuticals for the treatment of OCD and encourages further research into their effectiveness and their place within current treatment guidelines for OCD.

Funding

BioCeuticals® and Blackmores Institute unconditionally provided the study's interventional product free of charge. They were not involved in the study's conception, design, conduct, data-analysis, nor publication of the results.

Contributors

Jerome Sarris, LC and GO were primarily involved in the first iteration of the manuscript. LC analysed the data. All other co-authors participated in the editing and final approval of the manuscript.

Disclosure information:

Accepted Manuscript: Authors' Copy

Jerome Sarris has received either presentation honoraria, travel support, clinical trial grants, book royalties, or independent consultancy payments from: Integria Healthcare & MediHerb, Pfizer, Scius Health, Key Pharmaceuticals, Taki Mai, Fiji Kava, FIT-BioCeuticals®, Blackmores, Soho-Flordis, Healthworld, HealthEd, HealthMasters, Kantar Consulting, Grunbiotics, Australian Natural Therapeutics Group, Polistudium (Italy), Research Reviews, Elsevier, Chaminade University, International Society for Affective Disorders, Complementary Medicines Australia, SPRIM, Terry White Chemists, ANS, Society for Medicinal Plant and Natural Product Research, Sanofi-Aventis, Omega-3 Centre, the National Health and Medical Research Council, CR Roper Fellowship. **Michael Berk** has received Grant/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Abbot, Astra Zeneca, Janssen and Janssen, Lundbeck and Merck and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Janssen and Janssen, Lundbeck Merck, Pfizer and Servier – all unrelated to this work. **Chee Ng** had served as a consultant for Lundbeck, Grunbiotics, Servier, Janssen-Cilag, Wyeth and Eli Lilly, received research grant support from Wyeth and Lundbeck, and speaker honoraria from Servier, Lundbeck, Bristol-Myers Squibb, Organon, Eli Lilly, GlaxoSmithKline, Janssen- Cilag, Astra-Zeneca, Wyeth, and Pfizer, all outside and unrelated to this work. **Gerard Byrne** has received, through his employer, grant income from Eli Lilly, Janssen-Cilag, Biogen, the Australian National Health and Medical Research Council, and the Royal Brisbane and Women's Hospital. He has received royalties from book sales and licensing fees for the use of psychometric scales.

Accepted Manuscript: Authors' Copy

As a medical research institute, NICM Health Research Institute receives research grants and donations from foundations, universities, government agencies, individuals, and industry. Sponsors and donors also provide untied funding for work to advance the vision and mission of the Institute. Georgina Oliver, Lachlan Cribb, Scott Blair-West, David Castle, Olivia Dean, David Camfield, Vlasios Brakoulis, Chad Bousman, Nathan Dowling, Carolyn Ee, Jenifer Murphy, Ranjit Menon, Suneel Chamoli, and Mark Boschen, do not have any disclosures.

Acknowledgements

Thanks are extended to the much-appreciated participants in this study. JS is supported by an NHMRC Clinical Research Fellowship (APP1125000). MB is supported by a NHMRC Senior Principal Research Fellowship (1156072).

References

1. Fineberg NA, Hollander E, Pallanti S, et al. Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. *Int Clin Psychopharmacol*. 2020;35(4):173-193.
2. Skapinakis P, Caldwell DM, Hollingworth W, et al. Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. *Lancet Psychiatry*. 2016;3(8):730-739.
3. Knopp J, Knowles S, Bee P, et al. A systematic review of predictors and moderators of response to psychological therapies in OCD: do we have enough empirical evidence to target treatment? *Clin Psychol Rev*. 2013;33(8):1067-1081.
4. Pittenger C, Bloch MH. Pharmacological treatment of obsessive-compulsive disorder. *Psychiatr Clin North Am*. 2014;37(3):375-391.
5. Husted DS, Shapira NA. A review of the treatment for refractory obsessive-compulsive disorder: from medicine to deep brain stimulation. *CNS Spectr*. 2004;9(11):833-847.
6. Kariuki-Nyuthe C, Gomez-Mancilla B, Stein DJ. Obsessive compulsive disorder and the glutamatergic system. *Curr Opin Psychiatry*. 2014;27(1):32-37.
7. Kandemir H, Abuhandan M, Aksoy N, et al. Oxidative imbalance in child and adolescent patients with obsessive compulsive disorder. *Journal of Psychiatric Research*. 2013;47:1831-1834.
8. Sarris J, Murphy J, Mischoulon D, et al. Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. *Am J Psychiatry*. 2016;173(6):575-587.

9. Sarris J, Logan AC, Akbaraly TN, et al. Nutritional medicine as mainstream in psychiatry. *The Lancet Psychiatry*. 2015;2(3):271-274.
10. Baker DA, McFarland K, Lake RW, et al. N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. *Ann N Y Acad Sci*. 2003;1003:349-351.
11. Madayag A, Lobner D, Kau KS, et al. Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. *J Neurosci*. 2007;27(51):13968-13976.
12. Kupchik YM, Moussawi K, Tang XC, et al. The effect of N-acetylcysteine in the nucleus accumbens on neurotransmission and relapse to cocaine. *Biol Psychiatry*. 2012;71(11):978-986.
13. Schmaal L, Veltman DJ, Nederveen A, et al. N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study. *Neuropsychopharmacology*. 2012;37(9):2143-2152.
14. McQueen G, Lally J, Collier T, et al. Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia. *Psychopharmacology (Berl)*. 2018;235(10):3045-3054.
15. Lardner AL. Neurobiological effects of the green tea constituent theanine and its potential role in the treatment of psychiatric and neurodegenerative disorders. *Nutr Neurosci*. 2014;17(4):145-155.
16. Kakuda T, Hinoi E, Abe A, et al. Theanine, an ingredient of green tea, inhibits [3H]glutamine transport in neurons and astroglia in rat brain. *J Neurosci Res*. 2008;86(8):1846-1856.
17. Kakuda T, Nozawa A, Sugimoto A, et al. Inhibition by theanine of binding of [3H]AMPA, [3H]kainate, and [3H]MDL 105,519 to glutamate receptors. *Biosci Biotechnol Biochem*. 2002;66(12):2683-2686.
18. Szewczyk B, Kubera M, Nowak G. The role of zinc in neurodegenerative inflammatory pathways in depression. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011;35(3):693-701.
19. Bancila V, Nikonenko I, Dunant Y, et al. Zinc inhibits glutamate release via activation of pre-synaptic K channels and reduces ischaemic damage in rat hippocampus. *J Neurochem*. 2004;90(5):1243-1250.
20. Peters S, Koh J, Choi DW. Zinc selectively blocks the action of N-methyl-D-aspartate on cortical neurons. *Science*. 1987;236(4801):589-593.
21. Takeda A, Hirata M, Tamano H, et al. Release of glutamate and GABA in the hippocampus under zinc deficiency. *J Neurosci Res*. 2003;72(4):537-542.
22. Bagchi D, Vuchetich PJ, Bagchi M, et al. Protective effects of zinc salts on TPA-induced hepatic and brain lipid peroxidation, glutathione depletion, DNA damage and peritoneal macrophage activation in mice. *Gen Pharmacol*. 1998;30(1):43-50.
23. Gropper SS, Smith JL. Advanced Nutrition and Human Metabolism: Seventh Edition. *Wadsworth*. 2016.
24. Sayyah M, Olapour A, Saeedabad Y, et al. Evaluation of oral zinc sulfate effect on obsessive-compulsive disorder: a randomized placebo-controlled clinical trial. *Nutrition*. 2012;28(9):892-895.
25. Shohag H, Ullah A, Qusar S, et al. Alterations of serum zinc, copper, manganese, iron, calcium, and magnesium concentrations and the complexity of interelement relations in patients with obsessive-compulsive disorder. *Biol Trace Elem Res*. 2012;148(3):275-280.

- 606 26. Rayman MP. Selenium and human health. *Lancet*. 2012;379(9822):1256-1268.
- 607 27. Ozdemir E, Cetinkaya S, Ersan S, et al. Serum selenium and plasma malondialdehyde
608 levels and antioxidant enzyme activities in patients with obsessive-compulsive disorder.
609 *Prog Neuropsychopharmacol Biol Psychiatry*. 2009;33(1):62-65.
- 610 28. Savaskan NE, Brauer AU, Kuhbacher M, et al. Selenium deficiency increases susceptibility
611 to glutamate-induced excitotoxicity. *FASEB J*. 2003;17(1):112-114.
- 612 29. Kang SW, Choi SK, Park E, et al. Neuroprotective effects of magnesium-sulfate on
613 ischemic injury mediated by modulating the release of glutamate and reduced of
614 hyperreperfusion. *Brain Res*. 2011;1371:121-128.
- 615 30. Furukawa Y, Kasai N, Torimitsu K. Effect of Mg²⁺ on neural activity of rat cortical and
616 hippocampal neurons in vitro. *Magnes Res*. 2009;22(3):174S-181S.
- 617 31. Sartori SB, Whittle N, Hetzenauer A, et al. Magnesium deficiency induces anxiety and HPA
618 axis dysregulation: modulation by therapeutic drug treatment. *Neuropharmacology*.
619 2012;62(1):304-312.
- 620 32. Murck H. Magnesium and affective disorders. *Nutr Neurosci*. 2002;5(6):375-389.
- 621 33. Ueland PM, McCann A, Midttun O, et al. Inflammation, vitamin B6 and related pathways.
622 *Mol Aspects Med*. 2016.
- 623 34. Kennedy DO. B Vitamins and the Brain: Mechanisms, Dose and Efficacy--A Review.
624 *Nutrients*. 2016;8(2):68.
- 625 35. WMA. [The Helsinki Declaration of the World Medical Association (WMA). Ethical
626 principles of medical research involving human subjects]. *Pol Merkur Lekarski*.
627 2014;36(215):298-301.
- 628 36. Castle D, Bosanac P, Rossell S. Treating OCD: what to do when first-line therapies fail.
629 *Australas Psychiatry*. 2015;23(4):350-353.
- 630 37. Pallanti S, Marras A, Salerno L, et al. Better than treated as usual: Transcranial magnetic
631 stimulation augmentation in selective serotonin reuptake inhibitor-refractory obsessive-
632 compulsive disorder, mini-review and pilot open-label trial. *J Psychopharmacol*.
633 2016;30(6):568-578.
- 634 38. Bruno A, Pandolfo G, Cedro C, et al. Effect of Ziprasidone Augmentation of Serotonin
635 Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: A 12-Week,
636 Open-Label Uncontrolled Preliminary Study. *Clin Neuropharmacol*. 2016;39(1):6-9.
- 637 39. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-
638 compulsive disorder: an open trial. *J Clin Psychiatry*. 2002;63(9):796-801.
- 639 40. Bakhla AK, Verma V, Soren S, et al. An open-label trial of memantine in treatment-
640 resistant obsessive-compulsive disorder. *Ind Psychiatry J*. 2013;22(2):149-152.
- 641 41. Khan A, Kolts RL, Rapaport MH, et al. Magnitude of placebo response and drug-placebo
642 differences across psychiatric disorders. *Psychological Medicine*. 2005;35(5):743-749.
- 643 42. Sugarman MA, Kirsch I, Huppert JD. Obsessive-compulsive disorder has a reduced
644 placebo (and antidepressant) response compared to other anxiety disorders: a meta-
645 analysis.". *Journal of affective disorders*. 2017;2018:217-226.
- 646 43. Brodey BB, First M, Linthicum J, et al. Validation of the NetSCID: an automated web-
647 based adaptive version of the SCID. *Compr Psychiatry*. 2016;66:67-70.
- 648 44. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive
649 Scale. I. Development, use, and reliability. *Arch Gen Psychiatry*. 1989;46(11):1006-1011.

45. Rapp AM, Bergman RL, Piacentini J, et al. Evidence-Based Assessment of Obsessive-Compulsive Disorder. *J Cent Nerv Syst Dis*. 2016;8:13-29.
46. Abramowitz JS, Deacon BJ, Olatunji BO, et al. Assessment of obsessive-compulsive symptom dimensions: development and evaluation of the Dimensional Obsessive-Compulsive Scale. *Psychol Assess*. 2010;22(1):180-198.
47. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. *J Consult Clin Psychol*. 1988;56(6):893-897.
48. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. *Int Clin Psychopharmacol*. 1996;11 Suppl 3:89-95.
49. Guy W. ECDEU Assessment Manual for Psychopharmacology. *US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration*. 1976.
50. Mohebbi M, Dodd S, Dean OM, et al. Patient centric measures for a patient centric era: Agreement and convergent between ratings on The Patient Global Impression of Improvement (PGI-I) scale and the Clinical Global Impressions - Improvement (CGI-S) scale in bipolar and major depressive disorder. *Eur Psychiatry*. 2018;Sep(53):17-22.
51. WHO. Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. *Psychol Med*. 1998;28(3):551-558.
52. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. *Psychopharmacol Bull*. 1986;22(2):343-381.
53. Bates D, Sarkar D, Bates MD, et al. The lme4 package. *R package version*. 2007;2(1):74.
54. Buuren SV, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. *Journal of statistical software*. 2010:1-68.
55. Mataix-Cols D, de la Cruz LF, Nordsletten AE, et al. Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder. *World Psychiatry*. 2016;15(1):80.
56. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. 1992.
57. Fisher PL, Wells A. How effective are cognitive and behavioral treatments for obsessive-compulsive disorder? A clinical significance analysis. *Behaviour research and therapy*. 2005;43(12):1543-1558.
58. Hedeker D, Gibbons RD. Application of random-effects pattern-mixture models for missing data in longitudinal studies. *Psychological methods*. 1997;2(1):64.
59. Team RC. R: A language and environment for statistical computing. In: Vienna, Austria; 2013.
60. Lüdtke D. sjPlot: Data visualization for statistics in social science. *R package version*. 2018;2(1).
61. Wickham H. *ggplot2: elegant graphics for data analysis*. springer; 2016.
62. Fournier J, DeRubeis R, Hollon S, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. *JAMA*. 2010;303(1):47-53.
63. Koran LM, Aboujaoude E, Gamel NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. *The Journal of clinical psychiatry*. 2009;70(11):1530-1535.

Accepted Manuscript: Authors' Copy

64. Shams J, Soufi ES, Zahiroddin A, et al. Using caffeine on the patients as therapeutic option against treatment-resistant obsessive-compulsive disorder. *Journal of family medicine and primary care*. 2019;8(5):1741.
65. Bryan J. Psychological effects of dietary components of tea: caffeine and L-theanine. *Nutrition reviews*. 2008;66(2):82-90.
66. Oliver G, Dean O, Camfield D, et al. N-Acetyl Cysteine (NAC) in the Treatment of Obsessive Compulsive and Related Disorders: A Systematic Review. *Clinical Psychopharmacology and Neuroscience*. 2014;13 (1):12-24.
67. Gadallah A-HA, Ebada MA, Gadallah A, et al. Efficacy and safety of N-acetylcysteine as add-on therapy in the treatment of obsessive-compulsive disorder: A systematic review and meta-analysis. *Journal of Obsessive-Compulsive and Related Disorders*. 2020;25:100529.
68. Sarris J, Oliver G, Camfield DA, et al. N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study. *CNS Drugs*. 2015;29(9):801-809.
69. Sarris J, Oliver G, Camfield D, et al. Participant Characteristics as Modifiers of Response to N-Acetyl Cysteine (NAC) in Obsessive-Compulsive Disorder. . *Clinical Psychological Science*. 2016;Accepted 10/2/2016.
70. Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. *J Psychiatr Res*. 2011;45(5):626-629.
71. Ernst E, Resch KL. Concept of true and perceived placebo effects. *Bmj*. 1995;311(7004):551-553.
72. Diniz JB, Shavitt RG, Fossaluza V, et al. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. *Journal of clinical psychopharmacology*. 2011;31(6):763-768.
73. Jakubovski E, Diniz JB, Valerio C, et al. Clinical predictors of long-term outcome in obsessive-compulsive disorder. *Depression and anxiety*. 2013;30(8):763-772.
74. NHMRC. Nutrient Reference Values for Australia and New Zealand. <https://www.nrv.gov.au/nutrients>. Published 2017. Accessed 15/05/2021, 2021.

Table 1 – Nutraceutical dosage regime in the TRON study

Nutrient/s	Amount	Dose (elemental) per day	Recommended daily intake ¹
NAC & L-theanine capsules	2-3* capsules twice per day	2,000mg-3,000mg NAC; 400-600mg L-theanine*	N/A
Zinc liquid	25 drops per day, in water	28mg elemental zinc	Males: 14mg Females: 8mg
Selenium liquid	5 drops per day, in water	113mcg elemental selenium	Males: 70mcg Females: 60mcg
Magnesium + P5P	1 tablet per day	150mg elemental magnesium; 50mg P5P	<u>Magnesium</u> Males: 420mg Females: 310mg <u>P5P</u> [^] Males: 1.7mg Females: 1.3mg

*At Week-8, the NAC & L-theanine capsules were titrated from 2 to 3 capsules, twice per day in the event of non-response ($\leq 35\%$ reduction from baseline YBOCS score). ¹ Recommended daily intakes are taken from the Nutrient Reference Values for Australian and New Zealand.⁷⁴ N/A = not applicable; NAC = N-acetyl cysteine; P5P = Pyridoxal-5'-phosphate. ^ Based on B6 RDI levels

730 Table 2. Baseline participant characteristics

<i>Characteristic</i>	<i>Summary</i>
Age, mean (SD)	38.5 (12.0)
BMI, mean (SD)	26.2 (5.52)
Female sex, n (%)	13 (46.4%)
Married, n (%)	8 (28.6%)
Education	
High school graduate or early leaver	5 (17.8%)
College certificate/diploma	10 (35.7%)
University graduate/post-graduate	13 (46.4%)
Employment status	
Employed/student	17 (60.7%)
Unemployed	11 (39.3%)
Ancestry	
European	22 (78.6%)
Middle eastern	2 (7.14%)
Americas	2 (7.14%)
Other	4 (14.3%)
<i>OCD treatment history</i>	
Chronicity of OCD (years), median (IQR)	17.5 (13)
Number of unsuccessful prior medication trials, median (IQR), min-max	7 (1.5), 4 – 15
Prior psychotherapy, n (%)	28 (100%)
Exposure and response prevention, n (%)	18 (64.3%)
OCD in-patient programs, n (%)	5 (17.9%)
Current medication	
SSRI or SNRI, n (%) ¹	21 (75.0%)
Antipsychotic, n (%) ²	6 (21.4%)
Benzodiazepine, n (%) ³	7 (25.0%)
Atypical, tricyclic or other antidepressant, n (%) ⁴	7 (25.0%)

731 ¹ citalopram (n = 1), escitalopram (n = 4), fluoxetine (n = 3), fluvoxamine (n = 3), paroxetine (n =
732 1), sertraline (n = 7), venlafaxine (n = 1), desvenlafaxine (n = 1); ² quetiapine (n = 4), risperidone
733 (n = 1), aripiprazole (n = 1); ³ alprazolam (n = 1) lorazepam (n = 2), diazepam (n = 2), clonazepam

Accepted Manuscript: Authors' Copy

(n = 1);⁴ clomipramine (n = 4), amitriptyline (n = 1), mirtazapine (n = 1), agomelatine (n = 1), lithium (n = 1)

Table 3. Baseline psychological features

<i>Baseline characteristic</i>	<i>Summary</i>
YBOCS total, mean (SD)	25.9 (5.07)
YBOCS obsessions subscale, mean (SD)	12.6 (2.33)
YBOCS compulsions subscale, mean (SD)	13.3 (3.30)
DOCS total, mean (SD)	37.4 (16.4)
BAI total, mean (SD)	21.1 (13.3)
SIGHD total, mean (SD)	12.7 (8.08)
SDS total, mean (SD)	17.2 (7.12)
WHOQOL-BREF item 1, n(%)*	
Very poor	0
Poor	10 (37.0%)
Neither poor nor good	9 (33.3%)
Good	8 (29.6%)
Very good	0

* "How would you rate your quality of life?"

BAI = Beck Anxiety Inventory; DOCS = Dimensional Obsessive-Compulsive Scale; SDS = The Sheehan Disability Scale; SIGHD = Structured Interview Guide for the Hamilton Depression Rating Scale; WHOQOL-BREF = World Health Organization Quality of Life – BREF; YBOCS = Yale-Brown Obsessive-Compulsive Scale

Figure 1. Treatment response on total YBOCS by baseline severity
Treatment response on the YBOCS at the 20th (20.6), 50th (26.0) and 80th percentiles (28.6) of baseline total YBOCS severity. YBOCS= Yale-Brown Obsessive-Compulsive Scale.

139x95mm (300 x 300 DPI)

Figure 2

Figure 2. Treatment response on total DOCS by baseline severity
 Treatment response on the DOCS at the 20th (18.0), 50th (33.5) and 80th percentiles (49.4) of baseline
 DOCS severity. DOCS= Dimensional Obsessive-Compulsive Scale

124x85mm (300 x 300 DPI)

789 Table 4. Estimated mean follow-up scores for primary and secondary outcomes

<i>Measure</i>	Week-4		Week-8		Week-12		Week-16		Week-20		Estimated change score (95%
	mean (95% CI)		mean (95% CI)		mean (95% CI)		mean (95% CI)		mean (95% CI)		CI)
	<i>n</i> = 23		<i>n</i> = 23		<i>n</i> = 17		<i>n</i> = 13		<i>n</i> = 13		
YBOCS total	23.0	(21.1, 24.9)	21.8	(20.0, 23.6)	20.6	(18.8, 22.4)	19.4	(17.5, 21.3)	18.2	(16.1, 20.3)	-7.13 (-9.24, -5.01, $p < 0.001$)
YBOCS obsession	11.4	(10.4, 12.5)	10.8	(9.78, 11.7)	10.1	(9.11, 11.1)	9.45	(8.38, 10.5)	8.79	(7.57, 10.0)	-3.61 (-4.83, -2.39, $p < 0.001$)
YBOCS compulsion	11.6	(10.4, 12.7)	11.0	(9.91, 12.2)	10.5	(9.36, 11.6)	10.0	(8.77, 11.1)	9.40	(8.14, 10.7)	-3.50 (-4.76, -2.24, $p < 0.001$)
DOCS	32.1	(28.7, 35.5)	30.8	(27.6, 33.9)	29.4	(26.3, 32.6)	28.1	(24.7, 31.6)	26.8	(22.8, 30.8)	-9.23 (-13.2, -5.25, $p < 0.001$)
SIGHD	9.98	(8.57, 11.4)	9.14	(7.92, 10.4)	8.30	(7.06, 9.54)	7.46	(6.02, 8.90)	6.62	(4.84, 8.40)	-5.38 (-7.16, -3.59, $p < 0.001$)
BAI	17.4	(14.7, 20.1)	15.8	(13.2, 18.3)	14.1	(11.6, 16.7)	12.5	(9.78, 15.3)	10.9	(7.84, 14.0)	-9.80 (-12.9, -6.73, $p < 0.001$)
SDS	13.8	(12.2, 15.4)	13.0	(11.5, 14.4)	12.1	(10.6, 13.6)	11.2	(9.59, 12.8)	10.3	(8.47, 12.2)	-4.69 (-6.55, -2.83, $p < 0.001$)

790 Follow-up means and 95% confidence intervals are estimated from linear mixed effects models adjusted for baseline score. All follow
791 up means and change scores are calculated with baseline score at its mean value.

Accepted Manuscript: Authors' Copy

792 BAI = Beck Anxiety Inventory; DOCS = Dimensional Obsessive-Compulsive Scale; SDS = The Sheehan Disability Scale; SIGHD =
793 Structured Interview Guide for the Hamilton Depression Rating Scale; WHOQOL-BREF = World Health Organization Quality of Life –
794 BREF; YBOCS = Yale-Brown Obsessive-Compulsive Scale